The Nexus platform combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single, fully integrated platform that was also designed to accommodate future solutions.
The Nexus platform is driven by a new proprietary digital algorithm that results in more power, efficiency and control, according to the Farmingdale, N.Y.-based ultrasound device maker. Nexus incorporates RF capabilities, allowing for use in general surgery procedures, as well as smart technology designed to allow for easier setup and use. Nexus’ increased power may improve tissue resection rates, in concert with its proprietary digital algorithm to perform more efficient bone removal procedures, the company said.
“We are very pleased to report CE Mark approval for Nexus, as we continue to expand our footprint and diversify our revenue across markets and procedures,” said Misonix president & CEO Stavros Vizirgianakis in a news release. “Nexus marks an important leap forward for our company, as we are bringing to market a powerful and highly integrated, easy-to-use system that we are confident will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology for increased efficiency and efficacy. Given the important benefits Nexus brings to both physicians and patients, we are confident that our ability to enter the European market will help deliver improved outcomes for treatments across spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. In addition, the CE certification is important to supporting continued long-term growth across our recurring consumables revenue stream and in equipment product sales.”
The FDA cleared the Nexus system in June.